The Personalized Medicine Foundation and CancerConnect are pleased to provide patients and caregivers the opportunity to ask questions about the role of Circulating Tumor DNA (ctDNA) in the Management of Cancer. We have put together a panel of leading cancer experts to answer questions and publish a forum for the exchange of information.​

  • Submit Your Questions Here....
Image placeholder title

John Strickler, M.D., Associate Professor of Medicine, Associate Director Clinical Research – GI Oncology, Co-Leader, Duke Cancer Institute Molecular Tumor Board, Duke University

Image placeholder title

Daniel H. Ahn, D.O., M.S.,Assistant Professor of Medicine, Division of Hematology/Medical Oncology, Lead of GI Oncology Translational Research Disease Working Group, Board of Directors Member, ACCRU consortium


Cancer is caused by genetic mutations, and these mutations can be detected by measuring circulating tumor DNA, or ctDNA, in the blood. Detection of ctDNA allows for personalized cancer surveillance based on an individual’s unique set of tumor mutations.

Traditionally, the most common way to detect the presence of cancer has been through the use of imaging techniques like computerized tomography (CT) scan, magnetic resonance imaging (MRI), and positron emission tomography (PET). However, these imaging tools are limited in their ability to detect molecular residual disease (MRD), or very small traces of cancer in the body. ctDNA can be detected in the blood long before it appears on a CT or MRI scan.

Knowing if there are traces of cancer present in your body can help your oncologist decide:

  • Your best initial treatment
  • If you are responding to treatment
  • If further cancer treatment needs to be considered
  • If there are signs that the cancer has returned or progressed

What is circulating tumor DNA (ctDNA)?

Circulating tumor DNA (ctDNA) is 150–200-base-pair fragments of DNA, which originate from cancer cells and are present in the bloodstream or other body fluids.

How is ctDNA different than cfDNA?

Cell-free DNA (cfDNA) is all the DNA in the bloodstream including germline DNA and tumor DNA. ctDNA is the portion of cfDNA that is derived specifically from the tumor.

How can ctDNA help manage cancer?

There are currently four clinical applications of ctDNA to guide precision medicine in patients with cancer:

  • Detection of minimal residual disease (MRD) following surgery.
  • Monitoring the treatment response in the metastatic setting.
  • Identifying genomic drivers of therapeutic sensitivity and resistance.
  • Guiding treatment strategies to overcome resistance to treatment.

How is ctDNA used for the management of early-stage cancers?

Across all stages of surgically removed cancer, detection of ctDNA following surgery is a strong predictor of cancer recurrence. The detection of ctDNA could lead clinicians to intensify therapy in certain situations. Conversely, the absence of ctDNA could provide an opportunity to minimize surveillance or adjuvant treatment.

How is ctDNA used for the management of metastatic cancer?

ctDNA can be used to monitor treatment response, identify genomic drivers of treatment sensitivity or resistance, or identify new therapies that could overcome genomic drivers of treatment resistance.

When should ctDNA be collected?

Both tissue and blood samples are required initially to build the ctDNA test. Once the test is built, only blood samples are required for the periodic follow-up tests performed to monitor for MRD or recurrence. Since DNA assays require ctDNA shedding into the bloodstream, the performance of ctDNA assays is improved when blood is collected after—rather than during—active chemotherapy.

What is the procedure for ordering a ctDNA test?

Currently ctDNA testing must be requested by a provider so the test can be sent to the company performing the test. Patients cannot order this test. Only a physician can order the test.

Is ctDNA different from NGS testing?

“Next Generation Sequencing,” or “NGS” is a platform that allows simultaneous testing of multiple molecular targets. NGS testing can be performed on tumor tissue or blood (ctDNA).

If my doctor orders NGS testing on tumor tissue, will ctDNA testing also be performed?

Not always - ctDNA is typically a separate test and will usually not be ordered together with NGS testing unless specifically requested. Providers and hospitals use a variety of different companies to perform DNA testing. Some companies, like Natera perform both ctDNA and NGS testing, while others do not.

Does insurance pay for ctDNA testing?

Each insurance company is different. Medicare has begun paying for ctDNA testing with Signatera™ for Stage II-III colon cancer. For questions or financial assistance, individuals can contact Natera’s Patient Coordinators.

Phone: 650.489.9050 Fax: 650.412.1962


Recommended Articles

Image placeholder title

Dietary Supplements and Cancer - What You Need to Know

Understanding dietary supplements - an interview with DrRichard Tsong Lee Director of Integrative Medicine MDACC

Patient-Submitted Questions

Does a ctDNA positive test indicate a recurrence is probable or certain at some point without further treatment?

If a ctDNA test is positive, there is a strong likelihood for recurrence, but not certain. The likelihood for recurrence is around 80%. Meaning, if the test is positive, the chance for recurrence is approximately 80%. However, 20% of patients who test positive will not have recurrence. The 20% can potentially be cured with adjuvant chemotherapy after their surgery.

If you have Colon Cancer AND Ovarian Cancer how much would a negative Signatera ctDNA result, based on the Colon Cancer's tumor cells, also show probable absence of ctDNA for the Ovarian Cancer? My understanding is that Colon Cancer mutations show about a 60% similarity to Ovarian Cancer mutations. 

I have early stage colon cancer and want to test for residual disease. Is Signatera or Reveal more sensitive and specific?

To this point Signatera and Reveal have not been compared head-to-head. The specificity for Reveal and Signatera is excellent... approaching 100%. The sensitivity for Signatera is excellent - data is limited for Reveal.

Is ctDNA testing available for endometrial or other cancers?

Tumor informed MRD detection is possible for any advanced solid tumor. The test is tumor type “agnostic”. There just needs to be enough sample to identify 16 clonal variants. The test is run by Natera and needs to be ordered by a physician.

The test is increasingly used in the management of muscle invasive bladder cancer. The development of ctDNA tests and their clinical validation is an ongoing process. Data is available for over 30 tumor types, the bulk of which is in Colon, lung, bladder and breast cancer. Medicare now covers testing for stage II - III Colorectal cancer and and draft coverage for immunotherapy monitoring in pancreas cancer is pending. More information is available at

My wife has been recently under surgery for a colon cancer (2nd stage); after 8 months from surgery she just received a negative signatera test. As she still has an inflammatory process affecting many nodules in her lungs, my question for you is the following: is the signatera negative test stating she's now totally cancer-free or it states only that she's free from the primary colon cancer ? I'd like to know if her lung nodules could be cancer or she is totally cancer free at this time following the signatera test result. Thanks for your answer...!

The signatera test is “tumor informed” meaning it detects the actual DNA from the colon cancer that was diagnosed where ever that cancer is in the body. It does not detect DNA from other cancers. 

What if an initially negative ctDNA test converts to positive after surgery?

Through longitudinal assessment, if a negative ctDNA test were to become positive, this would be concerning for eventual disease recurrence (85-90%). The lead time is up to 8 months compared to CT scans and 3 months to CEA - within the 2-3 years recurrence risk would approach 100% after long-term follow up.

Can ctDNA replace CEA in Colon Cancer?

The sensitivity and specificity for ctDNA is much higher than CEA. Typically, if ctDNA is positive, it will be positive 3 months before a CEA is abnormal.

There are limitations for ctDNA as it does take more effort (sequencing and preparing a tumor-derived ctDNA assay for a patient), specific methods to draw and store the blood, where CEA can be done in most labs. Until there is more accessibility for ctDNA (MRD) for all patients, I would consider ctDNA as a complement to our available surveillance tools.

I had Signatera test then chemo for stage III colon cancer. Could this test replace CT/MRI imaging altogether? Why not just follow my ctDNA and get imaging scans if it becomes positive?

Signatera is strongly predictive of recurrence but it isn’t perfect. You could reduce the frequency of CT/MRI from a negative result, but national guidelines are still recommending scans at least annually for low risk patients with stage III disease.

Is there an understanding of what ctDNA positive means at it's minimal level. Is it like CEA in that the levels can vary or is it a yes or no result? Would a positive mean somewhere a fixed tumor is shedding cells? Any chance the nascent tumor location can be pinpointed based on resulting testing. Also, given the complexity of these tests, do Drs go on recommended treatment plans or do they make independent decisions? How many negatives would be needed to stop chemo, or, since getting chemo, are negative ctDNA less predictive? I guess these types of questions need major trials to be answered.

For MRD positivity, the assay is very sensitive and can detect as low as 0.1% of a MAF (mutant allele frequency). A positive result suggests that there is microscopic disease detected in the bloodstream. At this time, the assay is unable to specify where the cells are coming from. Since blood circulates throughout our whole body and we are testing for at one specific point in time, the tumor cells could be from anywhere within one's body.

At this time due to the test limitations (false negative rate), the results are prognostic and should be used on a case by case decision, rather than it being applicable for all. Clinical trials will help better ascertain whether MRD can be used to drive treatment decisions (intensifying chemotherapy in those with MRD positivity or de-escalating treatment in those who become MRD negative).

What tests are routinely ordered on colon cancer tissue removed during surgery?

DNA mismatch repair deficiency (MMR): Approximately 15% of stage I-III colorectal cancer diagnoses arise from the microsatellite instability (MSI) pathway, which is a consequence of deficient DNA mismatch repair (MMR). Deficient MMR (dMMR) can develop from an inherited germline mutation in a MMR gene (MLH1, MSH2, MSH6, PMS2)—Lynch Syndrome, for example—or, more commonly, can be due to epigenetic inactivation of the MLH1 gene and the CpG island methylator phenotype (CIMP). dMMR tumors are associated with a better stage-adjusted overall survival compared to proficient MMR (pMMR) tumors. MMR status may also be predictive for benefit from adjuvant chemotherapy and the type of chemotherapy patients will receive.

If I already had my cancer removed, can tissue from the surgery be obtained for ctDNA testing?

Most patients who have a cancer removed will have had tissue stored, which will be available for additional testing, including tumor somatic profiling, or to develop tumor-informed cell-free DNA profiling for MRD ctDNA assessment.

In tumor-informed assays, the primary tumor is sequenced to identify the patient-specific genomic alterations, upon which the primers for ctDNA testing in the plasma are designed to be based. Tumor-agnostic assays rely on a panel of preselected primers designed to detect known genomic alterations and epigenetic signatures relevant to CRC.

The likelihood for recurrence is around 80%. Meaning, if the test is positive, the chance for recurrence is approximately 80%. However, 20% of patients who test positive will not have recurrence. The 20% can potentially be cured with adjuvant chemotherapy after their surgery. The 20% who don't have a reoccurrence, in spite of testing positive for ctDNA, all received adjuvant treatment and this turned them negative on the ctDNA test? Does this mean the other 80% of positive ctDNA tested patients waited for CEA, CT, or other tests to find the reoccurrence?

In general, a positive test is a strong predictor of recurrence. That said, some patients with ctDNA+ disease after surgery have their outcome changed by adjuvant chemotherapy. If the ctDNA test remains positive after adjuvant chemotherapy, additional scans should be obtained to identify the active disease. If these tests are negative, a PET-CT would be reasonable. In some cases, the lesions can be removed with curative intent.

Are clinical trials available evaluating ctDNA testing?

Numerous clinical trials are currently underway to validate the role of ctDNA in selecting patients for adjuvant chemotherapy by addressing several questions:

  • Can adjuvant chemotherapy be omitted in patients who have no detectable ctDNA after surgery (treatment de-escalation)?
  • Could treatment escalation help in patients with detectable, post-operative ctDNA?
  • Does the clearance of ctDNA with adjuvant chemotherapy result in a cure?
  • Is ctDNA a predictive biomarker for treatment efficacy?
  • What is the best strategy to treat patients who continue to have detectable ctDNA after adjuvant chemotherapy?

Is ctDNA being used in Melanoma?

Circulating tumor DNA measurements before and during treatment could help guide selection of therapy for patients with BRAF V600-mutant metastatic melanoma.

Researchers assessed how well ctDNA levels prior to treatment, and at 4 weeks into treatment, predicted patient survival in 383 adults included in two melanoma clinical trials where patients were treated for BRAF V600 advanced metastatic melanoma.

Results showed that elevated baseline BRAF V600 mutation-positive ctDNA levels predicted worse survival and undetectable ctDNA at week 4 was significantly associated with improvements in survival and a delay in cancer progression. Future research should explore whether clinical decision-making, informed by ctDNA measurements, can improve patient survival compared to standard approaches, which rely primarily on radiographic scans.1



The Ask The Expert Series is made possible by support from The Personalized Medicine Foundation, Incyte Oncology, Abbvie, and CancerConnect. The "Ask The Expert" series is not medical advice nor is it a substitute for your doctor. It should serve as a guide to facilitate access to additional information and enhancement of a shared decision making process with your treating physician.